G protein-coupled receptors (GPCRs) are the largest family of cell-surface receptors, with more than 800 members identified thus far in the human genome. They regulate the function of most cells in the body, and represent approximately 3% of the genes in the human genome. These receptors respond to a wide variety of structurally diverse ligands, ranging from small molecules, such as biogenic amines, nucleotides and ions, to lipids, peptides, proteins, and even light. Ligands (agonists and antagonists) acting on GPCRs are important in the treatment of numerous diseases, including cardiovascular and mental disorders, retinal degeneration, cancer, and AIDS. It is estimated that these receptors represent about one third of the actual identified targets of clinically used drugs. The determination of rhodopsin crystal structure and, more recently, of opsin, 1 and 2 adrenergic and A2A adenosine receptors provides both academia and industry with extremely valuable data for a better understanding of the molecular determinants of receptor function and a more reliable rationale for drug design. GPCR structure and function constitutes a hot topic. The book, which lies between the fields of chemical biology, molecular pharmacology and medicinal chemistry, is divided into three parts. The first part considers what receptor structures tell us about the mechanism of receptor activation. Part II focuses on receptor function. It discusses what the data from biophysical and mutational studies, and the analysis of the interactions of the receptor with ligands and regulator proteins, tell us about the process of signal transduction. The final part, on modelling and simulation, details new insights on the link between structure and mechanism and their implications in drug design.
Jes·s Giraldo is based at the Institut de NeurociÞncies and Unitat de BioestadÝstica, Universitat Aut=noma de Barcelona. He works mainly in the field of mathematical modelling of GPCRs and has collaborated with a number of experimentalists, some of them leaders in the GPCR field. This has given him a deep understanding of the relationships between theory and experimentation in the area and a holistic view of the topic. Jean-Philippe Pin got his PhD in Molecular Biology from the University of Montpellier 2, France. He participated in the discovery of the metabotropic glutamate receptors and demonstrated synergism between various glutamate receptor subtypes for the activation of phospholipase A2. Subsequently, he worked as a post doctoral fellow at the Salk Institute where he cloned and characterized new mGlu receptor splice variants. In 1992, he set up a research team working on the structure function relationship of mGlu receptors in the CNRS laboratory in Montpellier. Currently, he heads the Molecular Pharmacology Department within the Institute of Functional Genomics, Montpellier, France where his research focuses on the molecular and cellular dynamics of GPCRs and has led to major new concepts in the GPCR field.
